Osel, Inc.
Mountain View, CA
- UEI
- R5DDHN86ANH9
- CAGE
- 4KCX1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 320 Logue Ave, Mountain View, CA 94043, USA
- Website
- oselinc.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel antimicrobial approach to treat chemoradiation resistant cervical cancer by selectively inhibiting lactobacillus… | National Cancer Institute | $279,852 | |
| Mucocept-CVN, a genetically enhanced vaginal lactobacillus strain for the prevention of HIV acquisition in women:… | National Institute of Allergy and Infectious Diseases | $2,391,049 | |
| Development of a rapid point of care diagnostic,to monitor mucocept-CVN, an HIV-targeted biotherapy, | National Institutes of Health | $225,000 | |
| Delivery of passive immunity against HIV using commensal vaginal lactobacillus BI | National Institutes of Health | $299,870 | |
| Delivery of passive immunity against HIV using commensal vaginal lactobacillus bioengineered to secrete broadly… | National Institutes of Health | $2,600,757 |
About Osel, Inc.
Osel, Inc. is a biotechnology company headquartered in Mountain View, California, specializing in developing live biotherapeutic products and innovative microbiome-based medical interventions. Registered in the System for Award Management (SAM) since 2006, the company focuses on advanced medical research and product development, particularly in the areas of women's health, infectious disease prevention, and cancer treatment. The organization operates as a for-profit corporate entity and has demonstrated expertise in developing sophisticated biological technologies that target specific medical challenges through genetic and microbial engineering approaches.
Through federal grant awards from agencies like the National Cancer Institute and the National Institute of Allergy and Infectious Diseases, Osel, Inc. has pursued groundbreaking research in several critical areas. The company has been developing novel interventions such as MUCOCEPT-CVN, a genetically enhanced Lactobacillus strain designed to prevent HIV acquisition in women, and GASK7B, a selective bacteriocin inhibitor targeting pathogenic Lactobacillus iners in cervical cancer treatment. These projects involve complex scientific work including genetic modification of bacterial strains, development of live biotherapeutic products, and preclinical research aimed at creating innovative medical solutions. Osel, Inc. has collaborated with prominent research institutions like the University of California, San Francisco (UCSF) on sub-award grants, participating in clinical trials, product development, laboratory analysis, and scientific research across multiple stages of investigation, from initial formulation to potential first-in-human clinical trials.
Quick answers
What is Osel, Inc.'s UEI?
Osel, Inc.'s Unique Entity ID (UEI) in SAM.gov is R5DDHN86ANH9.
What is Osel, Inc.'s CAGE code?
Osel, Inc.'s CAGE code is 4KCX1.
What is Osel, Inc.'s primary NAICS code?
Osel, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Osel, Inc. located?
Osel, Inc.'s physical address in SAM.gov is 320 Logue Ave, Mountain View, CA 94043, USA.
Is Osel, Inc. registered in SAM.gov?
Yes. Osel, Inc.'s SAM.gov registration is active through March 31, 2027.
What is Osel, Inc.'s most recent federal award?
Osel, Inc.'s most recent federal grant award is Novel antimicrobial approach to treat chemoradiation resistant cervical cancer by selectively inhibiting lactobacillus… (R43CA297979), from National Cancer Institute, on May 20, 2025.
On GovTribe
See Osel, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors